Sun Pharma Acquires Anti-inflammatory brand Phlogam from Aksigen Hospital Care
Phlogam administered orally, offers systemic enzyme-flavonoid therapy.
Mumbai: Drug major Sun Pharmaceutical Industries has announced that it has acquired anti-inflammatory brand Phlogam (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care, a Mumbai based research driven healthcare entity.
Phlogam is one of the first enzyme-bioflavonoid combination of Trypsin, Bromelain, and Rutoside (“TBR”) to complete a clinical study in India and get DCGI approval. It is approved by the DCGI for post-operative inflammation in patients undergoing minor surgery and dental procedures.
The acquisition is a part of three drug portfolio acquired from Aksigen with other brands being Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg)
Kirti Ganorkar, CEO-India business, Sun Pharma, said, “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds-up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation.”
The overall market of proteolytic enzyme for healing, pain and edema in India is around Rs.500 crores (as per IQVIA data MAT Nov 2022).
Actions of Trypsin, a proteolytic enzyme is primarily related to enhancing fibrinolysis by making more plasmin available for action. The addition of Bromelain, a proteolytic enzyme not only complements the fibrinolytic action of Trypsin, but also has broad-ranging effects of limiting vascular permeability (which can help counter edema), inhibiting platelet aggregation (which can help counter dysregulated coagulation and thrombosis) and limiting inflammatory cell infiltration. Rutoside a bioflavonoid, on the other hand, has far-reaching effects in controlling the oxidative stress, vascular permeability and countering the activation of and further release of inflammatory cytokines and chemokines.
When combined, these ingredients not only cover a wider range of processes involved in inflammation, but they also complement each other’s actions and provide a more well-rounded control of the inflammatory process. Overall, TBR, the systemic enzyme therapy, intervenes in different processes: the release of inflammatory mediators, the modulation of adhesion molecules, and the activation of fibrinolysis with consequent improved healing.
Phlogam administered orally, offers systemic enzyme-flavonoid therapy. The safety and efficacy of fixed-dose combination of trypsin, bromelain, and rutoside viz, Phlogam was assessed versus serratiopeptidase in 303 subjects with postoperative inflammation undergoing minor surgery and dental procedures. The study demonstrated systemic enzyme therapy with trypsin-bromelain-rutoside combination provided significantly better control and resolution of post-operative pain and inflammation, compared to serratiopeptidase. Phlogam provides the clinicians an evidence-based management solution for inflammation and pain management after minor surgery and dental procedures.
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by SUN Pharma.
